Over 60 per cent of New Zealanders have leftover or unwanted prescription medications in their home. Having excess medicine at home might be considered a good thing from a consumer's perspective, but the potential consequences of oversupply can be serious and need to be considered by the healthcare team.
Triazolam tablets are being discontinued; only endorsed prescriptions for existing patients are funded. Stocks of 125mcg tablets have run out, and 250mcg tablets will likely run out by November. Patients who take triazolam regularly will need to be withdrawn slowly, or changed to alternative medicine if continued treatment is necessary.
Immune-related adverse events are common with ICI therapy, can be serious, and can occur up to 90 days after the last dose. Therefore, it's important to be able to recognise signs and symptoms of adverse events in primary care. Our new resource supports you to do this.
Since originally publishing this article in September 2021, selegiline has been discontinued and supplies have been depleted. Rasagiline is now the only funded MAO-B inhibitor available in New Zealand.
This resource provides advice on prescribing and supplying rasagiline, which is currently funded but not yet approved by Medsafe.